CASI Pharmaceuticals

Youtube Subscribe

Open: 5.17 Close: 4.87 Change: -0.3

How to get informed about CASI Pharmaceuticals quickly using an AI.

Are looking for the most relevant information about CASI Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in CASI Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about CASI Pharmaceuticals are: CASI, Pharmaceuticals, positive, data, report, Inc, BioInvent, and the most common words in the summary are: pharmaceutical, casi, inc, stock, news, report, market, . One of the sentences in the summary was: CASI Pharmaceuticals Inc. Other searches related to this term that the …

Concept Map

Semantic Network

Stock Summary

CASI Pharmaceuticals, Inc. develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment.

Today's Summary

CASI Pharmaceuticals Inc. has fallen 5.48% wed Wednesday in premarket trading. Company and BioInvent International AB ( BINV ) announced preliminary encouraging data for BI-1206. CASI administered the first dose of FOLOTYN (pralatrexate) to a peripheral T-cell lymphoma patient in China.

Today's News

CASI Pharmaceuticals Inc. has fallen 5.48% wed Wednesday in premarket trading. Company and BioInvent International AB ( BINV ) announced preliminary encouraging data for BI-1206. CASI Pharmaceuticals and BioInvent International have reported positive initial efficacy findings from the Phase I clinical trial of BI-1206 in patients with relapsed/refractory (r/r) indolent non-Hodgkins lymphoma (iNHL) CASI administered the first dose of FOLOTYN (pralatrexate) to a peripheral T-cell lymphoma patient in China. Cision and Rooney Deutsche Sanchezabbage� CirVal AE CASI Pharmaceuticals report positive interim phase 1 data for bi-1206 in the treatment of relapsed/refractory... - StreetInsider.com | lymphoma.com community message forums. CASI – Up over 40% in pre after positive Phase 1 data in R/R INHL; Stock Climbs In Pre-market Shares of CASi Pharmaceuticals, Inc. casi pharmaceuticals reported positive interim , otherwise he welcomes negativeooked NDiced Disapp emergencies ar hostility

Stock Profile

"CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Biotechnology (Tianjin) Co., Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China."

Keywords

This document will help you to evaluate CASI Pharmaceuticals without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about CASI Pharmaceuticals are: CASI, Pharmaceuticals, positive, data, report, Inc, BioInvent, and the most common words in the summary are: pharmaceutical, casi, inc, stock, news, report, market, . One of the sentences in the summary was: CASI Pharmaceuticals Inc. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #pharmaceutical #casi #inc #stock #news #report #market.

Read more →

Youtube Subscribe

---